Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.

Hepatitis C is not spread through breast milk ... pegylated interferon (IFN), ribvirin (RBV), protease inhibitors such as boceprevir, telaprevir, simeprevir, and sofosbuvir and nucleotide polymer ...

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...

Enanta has a long heritage in the development of antiviral compounds, working with AbbVie on therapies for hepatitis C virus (HCV ... pandemic focusing on 3CL protease – the same target as ...

In 1996, one of the first protease inhibitor drugs indicated ... serious health issues in the following six areas: hepatitis C virus, neuroscience, immunology, oncology, renal disease and women's ...

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long ...

Nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; PK: Pharmacokinetics; RPV: Rilpivirine. Data taken from [10,33–38]. Blake Max's spouse is employed as a regional medical ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.

Expert Rev Vaccines. 2012;11(7):791-804.